• Royalty Pharma raised 2026 Portfolio Receipts guidance to $3.5 billion–$3.55 billion from $3.4 billion–$3.5 billion, its third consecutive quarterly increase.
• Royalty Receipts growth is now forecast at 10%–11%, versus 7%–10% previously, reflecting stronger portfolio momentum.
• Third-quarter Portfolio Receipts rose 9% to $890 million; Portfolio Cash Flow reached $673 million.
• Despite pelacarsen’s Phase 3 failure, the Ionis agreement provides $550 million in Spinraza royalty payments, a 1.1-times return on funding.
• The November 4, 2026, third-quarter earnings call featured CEO Pablo Legorreta, CFO Terrance Coyne, research chief Marshall Urist and analysts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royalty Pharma plc published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.